Document:

exv10w13w4

EXHIBIT 10.13.4

     XXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

AMENDMENT TO

STRATEGIC ALLIANCE AGREEMENT

     This AMENDMENT dated as of January 24, 2006 (the “Amendment”) to the Strategic Alliance
Agreement dated as of June 27, 2001, as amended to date , by and between TEVA PHARMACEUTICALS
CURACAO N.V., a Netherlands Antilles company (“Teva”), and IMPAX LABORATORIES, INC., a Delaware
corporation (“Impax”), (the “Strategic Alliance Agreement”). All capitalized terms used herein,
unless otherwise defined herein, shall have the respective meanings set forth in the Strategic
Alliance Agreement.

WITNESSETH

     WHEREAS, Impax and Teva are concurrently herewith entering into that certain agreement with
ANCHEN PHARMACEUTICALS, INC., a California corporation , respecting the Marketing in the U.S. of
Bupropion Products (the “Anchen Agreement”); and

     WHEREAS, Teva and Impax desire to hereby amend the Strategic Alliance Agreement so as to
reflect their agreement under and arising out of the Anchen Agreement.

     NOW, THEREFORE, in consideration of the foregoing premises and the mutual representations,
warranties, and covenants set forth in this Amendment and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

     Section 1.1. Amendments to Definitions.

          (a) Section 1.4 of the Strategic Alliance Agreement is hereby amended by adding the following
defined terms:

     “Anchen” — shall mean Anchen Pharmaceuticals, Inc., a California corporation.

     “Anchen Agreement” — shall mean that certain agreement, dated the same date hereof,
among Anchen, Teva and Impax, respecting the Marketing in the U.S. of Bupropion Products .

     “Anchen Product(s)” - shall mean the product(s) Marketed by Teva and /or its Affiliates
pursuant to the Anchen Agreement under Anchen’s ANDA No. 77-284 in the 150mg and 300mg
strengths (the “150mg Anchen Product” and “300mg Anchen Product,” respectively).

 

 

     “Bupropion Product(s)” — shall mean the Anchen Product(s) and the Impax Product(s) in
the 150mg and 300mg strengths (the “150mg Bupropion Product(s),” and “300mg Bupropion
Product(s),” respectively).

     “Impax Expense Percentage” - shall have the meaning set forth in Section 15.6.

     ”Impax Patent Litigation” — shall mean Biovail Laboratories International SRL v.
Impax Laboratories, Inc., Civil Action No. 05-1085 pending in the United States District
Court for the Eastern District of Pennsylvania.

     “Impax Product(s)” - shall mean the product(s) Marketed under Impax’s ANDA No. 77-415
in the 150mg and 300mg strengths (the “150mg Impax Product” and “300mg Impax Product,”
respectively).

     “Launch Quantities” — shall mean XXXXX tablets of the 300mg Impax Product.

          (b) Section 1.4.20 of the Strategic Alliance Agreement is hereby amended by adding the
following at the end thereof:

“; provided further, however, that with respect to the 300mg Bupropion Products, and, in the
event the Anchen Agreement is amended to include the 150mg Bupropion Products, with respect
to the 150mg Bupropion Products, such amount shall be equal to (a) for the Impax Products,
XXXXX percent (XXXXX%) of the Profit, increasing to XXXXX percent (XXXXX%) of the Profit
upon the later of (i) the date of a final, non-appealable order issued by a U.S. court of
competent jurisdiction in relation to the Impax Patent Litigation, that the Impax Products
do not infringe each of the patents at issue in the Impax Patent Litigation or that such
patents are invalid or unenforceable, and (ii) the date of the last quarterly payment by
Teva pursuant to Section 3.5 of the Anchen Agreement; and (b) for the Anchen Products, XXXXX
percent (XXXXX%) of the Profit.”

          (c) Section 1.4.21 of the Strategic Alliance Agreement is hereby amended by adding the
following at the end thereof:

“; and in addition to the foregoing, all amounts paid by Teva and/or its Affiliates to
Anchen and/or its Affiliates, and/or their respective directors, officers, shareholders,
employees, servants and agents, pursuant to Sections 8.1(d) and 8.1(e) (as related to patent
claims) of the Anchen Agreement.”

          (d) Section 1.4.32 of the Strategic Alliance Agreement is hereby amended by adding the
following at the end thereof:

“The “Bupropion (once daily)” Tier 3 Product shall consist of the Impax Products and the
Anchen Products.”

          (e) Section 1.4.33 of the Strategic Alliance Agreement is hereby amended by adding the
following at the end thereof:

2

 

“; provided, however, that with respect to the 300mg Bupropion Products and, in the event
the Anchen Agreement is amended to include the 150mg Bupropion Products, with respect to
the 150mg Bupropion Products, it shall be an amount equal to XXXXX,
except to the extent the payment obligations referenced in such Sections are expressly
provided for under this Agreement.”

     Section 1.2. Additional Amendments.

          (a) Section 11.1 of the Strategic Alliance Agreement is hereby amended by adding the following
after the first sentence thereof:

“; provided, however, that with regard to the Launch Quantities of each Impax
Product, in the event Impax may not lawfully, or Teva has instructed Impax not to,
deliver such Impax Product to Teva, then Impax shall store such Impax Product in
Impax’s warehouse until receipt of further instructions from Teva.”

          (b) Section 11.2.1 of the Strategic Alliance Agreement is hereby amended by:

(i) adding the following after the first sentence thereof:

“; provided, however, that in the event Impax is required to store the
Launch Quantities in its warehouse pursuant to Section 11.1 of this
Agreement, then Impax shall invoice Teva when such Launch Quantities are
shipped to its warehouse.”;

(ii) adding the following after the second sentence thereof:

“, or the receipt of Impax’s invoice, if the invoice is for Launch Quantities stored
in Impax’s warehouse.”

(iii) adding the following at the end thereof:

“Teva
shall, within thirty (30) days of receipt of Impax’s invoice therefor,
reimburse Impax XXXXX klucel required for the manufacture of
the Launch Quantities, XXXXX.”

          (c) Section 11.3 of the Strategic Alliance Agreement is hereby amended by adding the following
at the end thereof:

“XXXXX.”

3

 

          (d) The phrase “or under the Anchen Agreement” is hereby added at the end of Sections 14.1(a)
and 14.2(a) of the Strategic Alliance Agreement and after the word “hereunder” in Section 14.3 of
the Strategic Alliance Agreement.

          (e) Section 15.5 of the Strategic Alliance Agreement is hereby amended by adding the following
after the second sentence thereof:

          “Notwithstanding the foregoing, with respect to the Impax Products, Teva shall have the
obligation to assume direction and control of any Intellectual Rights Suit and the defense of
claims arising therefrom.”

          (f) Section 15.6 of the Strategic Alliance Agreement is hereby amended by adding the following
after the first sentence thereof:

     “; and provided further, however, that
with respect to Intellectual Rights Legal
Expenses incurred from and after the date hereof in connection with and/or arising out of
the Impax Patent Litigation, an Intellectual Rights Suit related to the Anchen Products, or
Sections 8.1(d) or 8.1(e) of the Anchen Agreement, Impax shall bear that XXXXX
payable with respect to the 300mg Bupropion Products during the first six
months following the Launch Date or, in the event the Anchen Agreement is amended to include
the 150mg Bupropion Products, XXXXX payable with respect
to the Bupropion Products during the first six months following the Launch Date of each
Bupropion Product (the “Impax Expense Percentage”) (not to exceed, however, the aggregate
Impax Margins paid or payable by Teva to Impax hereunder with respect to the Bupropion
Products) and Teva shall bear the balance of all such Intellectual Rights Legal Expenses.”

          (g) Section 16 of the Strategic Alliance Agreement is hereby amended by:

(i) adding the following after the first sentence thereof:

“; provided, however, that in connection with the Bupropion Products,
XXXXX”; and

(ii) adding the following at the end thereof:

“If legal proceedings are commenced by a third party against any such Regulatory
Authority seeking to delay the final Approval and/or Launch Date of the Impax
Products, Impax and Teva shall cooperate with one another in taking all reasonable
action in defense of such proceedings, including intervention in such proceedings,
and shall similarly jointly direct and control such action. XXXXX.”

4

 

          (h) The following provisions are hereby added to the Strategic Alliance Agreement:

“Section 2.20 Marketing of the Bupropion Products.

     2.20.1 In the event that on or before April 15, 2006, all of the following
conditions are met with respect to the 300mg Bupropion Product: (i) Impax’s ANDA no.
77-415 is eligible for final Approval upon the relinquishment by Anchen of its First
to File Exclusivity for its ANDA no. 77-284 or the selective waiver by Anchen of
such First to File Exclusivity in favor of Impax’s ANDA no. 77-415; (ii) Teva
believes in good faith, based upon communications with the FDA or a court order,
that Impax’s ANDA no. 77-415 is not subject to a thirty (30)-month stay pursuant to
21 U.S.C. Section 355(j)(5)(B)(iii); and (iii) Impax has, in accordance with Teva’s
firm purchase orders, manufactured and available for delivery to Teva and/or its
Affiliates Launch Quantities of the 300mg Impax Product, then, if and when Teva
and/or its Affiliates decide to Market such 300mg Bupropion Product, it shall Market
the 300mg Impax Product.

     2.20.2 If conditions (i), (ii) and (iii) under Section 2.20.1 are not met on
or before April 15, 2006 with respect to the 300mg Bupropion Product, or
alternatively the 300mg Impax Product is not available for Marketing in accordance
with Applicable Law, then notwithstanding anything contained in this Agreement to
the contrary, and subject to the provisions of Section 2.21 of this Agreement, Teva
and/or its Affiliates shall have sole discretion to decide from time to time whether
to Market the 300mg Impax Product and/or the 300mg Anchen Product, and if Teva
and/or its Affiliates decide to Market the 300mg Anchen Product, it may obtain all
quantities of such Anchen Product it requires from Anchen or its permitted designee.

     2.20.3 Notwithstanding anything contained in this Agreement to the contrary,
and subject to the provisions of Section 2.21 of this Agreement, in the event the
Anchen Agreement is amended to include the 150mg Bupropion Products, Teva and/or its
Affiliates shall have sole discretion to decide from time to time whether to Market
the 150mg Impax Product and/or the 150mg Anchen Product, and if Teva and/or its
Affiliates decide to Market the 150mg Anchen Product, it may obtain all quantities
of such Anchen Product it requires from Anchen or its permitted designee.”

     “Section 2.21 For each of the 300mg Bupropion Product, and, in the event the Anchen
Agreement is amended to include the 150mg Bupropion Products, the 150mg Bupropion Product,
if Teva and/or its Affiliates Market the Anchen Product pursuant to the provisions of this
Agreement, then the following shall apply:

5

 

     2.21.1 Within one hundred and thirty-five (135) days following the date of the
first commercial sale by Teva and/or its Affiliates of such Anchen Product, Teva
shall provide Impax with written notice advising whether Teva and/or its Affiliates
intend to either: (a) continue Marketing such Anchen Product, or (b) cease Marketing
such Anchen Product not later than one hundred and eighty one (181) days from the
date of such first commercial sale, and thereafter commence Marketing the same
strength Impax Product. If Teva does not provide such written notice to Impax, it
shall be deemed as if it provided notice advising of the intent to continue
Marketing such Anchen Product.

     2.21.2 In the event Teva has or is deemed to have provided notice under
Section 2.21.1 above of the intent to continue Marketing such Anchen Product, then
from and after such one hundred and eighty first (181) day: (a) the grant to Teva
with regard to the Marketing in the U.S. of the same strength Impax Product shall be
deemed nonexclusive, and the provisions of Sections 2.3 — 2.6 and 2.11 of this
Agreement shall no longer apply to Teva and/or Impax or their respective Affiliates
with regard to such Impax Product; provided, however, in any event, Impax shall
remain obligated to supply Teva’s and/or its Affiliates’ requirements of such Impax
Product; and (b) Teva and/or its Affiliates may decide from time to time in their
sole discretion to Market such Impax Product, in which event Impax shall supply the
Impax Product pursuant to firm purchase orders at a purchase price equal to XXXXX
percent (XXXXX%) of the applicable Manufacturing Costs, and such Impax Products
shall be deemed Anchen Products for purposes of determining the Impax Margin payable
with respect thereto.

     2.21.3 In the event Teva has provided notice under Section 2.21.1 above of the
intent to commence Marketing the applicable Impax Product, then Teva and/or its
Affiliates shall cease Marketing the same strength Anchen Product not later than
such one hundred and eighty first (181) day, and shall commence Marketing such Impax
Product subject to the terms and conditions of this Agreement (without regard to
Subsection 2.21.2(a) and (b) above). In the event Teva recommences Marketing such
Anchen Product after providing such notice, Subsections 2.21.2(a) and (b) above
shall apply from and after the date Teva has recommenced Marketing such Anchen
Product.”

          (i) The provisions of Sections 2.7, 2.8, 2.10, and 11.5 of the Strategic Alliance Agreement
shall be of no force or effect with respect to the 300mg Bupropion Products and, in the event the
Anchen Agreement is amended to include the 150mg Bupropion Products, the 150mg Bupropion Products.

          (j) Attachment A to the amendment dated March 24, 2005 to the Strategic Alliance Agreement is
hereby amended with respect to the 300mg Bupropion Products, and, in the event the Anchen Agreement
is amended to include the 150mg Bupropion Products, with respect to the 150mg Bupropion Products,
by adding the following at the end thereof:

	 	 	 	 	 
	 

	 	150mg Bupropion Product
	 	XXXXX%, provided, however, that Teva may adjust such percentage pursuant to Section

6

 

	 	 	 	 	 
	 

	 	 	 	1.4.26(b) on a quarterly basis
	 
	 

	 	300mg Bupropion Product
	 	XXXXX%, provided, however, that Teva may adjust such percentage pursuant to Section 1.4.26(b) on a quarterly basis

     Section 1.3. Miscellaneous 

          (a) Entire Agreement. The Strategic Alliance Agreement, as hereby amended, and the
Anchen Agreement, and any attachments thereto, constitute the entire agreement between the Parties
with respect to their subject matter and supersede all prior agreements, arrangements, dealings or
writings between the Parties. With respect to the Bupropion Products, if and to the extent there is
a conflict between the Anchen Agreement and the Strategic Alliance Agreement with respect to the
rights and obligations of Teva and Impax between themselves, then the provisions of the Strategic
Alliance Agreement, as amended hereby, shall control. This Amendment may not be amended or modified
except in writing executed by the duly authorized representatives of both Parties.

          (b) Effect of Amendment. All of the terms and conditions contained in the Strategic
Alliance Agreement, as hereby amended, shall remain in full force and effect. For the purposes of
clarity, this Amendment shall have no force and effect with regard to the 150mg Bupropion Products
unless and until the Parties enter into an agreement with Anchen respecting 150mg Bupropion
Products, and, furthermore, whenever in this Amendment reference is made to an “amendment to the
Anchen Agreement to include the 150mg Bupropion Products” the Parties hereby acknowledge and agree
that such phrase is intended to include an amendment, supplement or similar agreement among the
parties to the Anchen Agreement respecting the 150mg Bupropion Products.

          (c) Counterparts. This Amendment may be executed in two (2) or more counterparts, and
each such counterpart shall be deemed to be an original instrument, but such counterparts together
shall constitute one agreement.

[The remainder of this page is intentionally left blank]

7

 

     IN WITNESS WHEREOF, each of the Parties has executed this Amendment, all on the day and year
first above written.

	 	 	 	 	 
	 	TEVA PHARMACEUTICALS CURACAO N.V.

 	 
	 	By:  	/s/ Ido Weinstein
 	 
	 	 	Name:  	Ido Weinstein 	 
	 	 	Title:  	Managing Director 	 
	 
	 	 	 
	 	By:  	                                              /s/ [Illegible]
 	 
	 	 	Name:  	MeesPierson Trust (Curacao) B.V. 	 
	 	 	Title:  	Managing Director 	 
	 
	 	IMPAX LABORATORIES, INC.

 	 
	 	By:  	/s/  Barry R. Edwards
 	 
	 	 	Name:  	Barry R. Edwards 	 
	 	 	Title:  	CEO 	 
	 
	 	 	 
	 	By:  	                                              /s/  David S. Doll
 	 
	 	 	Name:  	David S. Doll 	 
	 	 	Title:  	Sr. Vice President 	 
	 

8exv10w13w5

EXHIBIT 10.13.5

     XXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

EXECUTION COPY

February 9, 2007

Impax Laboratories, Inc.

30831 Huntwood Avenue

Haywood, California 94544

Attention: Larry Hsu, Ph.D., President

Dear Dr. Hsu:

Reference is made to the Strategic Alliance Agreement, effective June 27, 2001, between Teva
Pharmaceuticals Curacao N.V. (“Teva”) and Impax Laboratories, Inc. (“Impax”), as amended to date
(collectively, the “Agreement”). All capitalized terms used herein, and not otherwise defined
herein, shall have the respective meanings set forth in the Agreement.

This shall confirm that effective as of the Effective Date, as defined in the Omnibus Agreement by
and among Teva, Impax, Anchen Pharmaceuticals, Inc. (“Anchen”) and Biovail Laboratories
International SRL (“Biovail”) dated the same date hereof concerning finished bupropion
hydrochloride extended release tablets (“Omnibus Agreement”), Teva and Impax agree as follows
(notwithstanding the foregoing, Teva and Impax hereby agree that if the Transaction Agreements (as
defined in the Omnibus Agreement) become null and void pursuant to Section 3.4 of the Omnibus
Agreement, this letter agreement shall also become null and void effective as of the date hereof):

(1) The Impax Margin with respect to the Bupropion Products shall be revised and, accordingly,
Section 1.1(b) of the amendment between Teva and Impax dated January 24, 2006 (“Amendment”) shall
be deleted in its entirety and replaced with the following:

“; provided further, however, that with respect to the Bupropion Products, such amount
shall be equal to:

(a) for the Impax Products, a percentage of the Profit according to the following chart:

 

 

EXECUTION COPY

	 	 	 
	PERIOD	 	IMPAX MARGIN
	Commencing on the Launch Date and ending three (3)
months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing three (3) months from the Launch Date and
ending six (6) months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing six (6) months from the Launch Date and
ending nine (9) months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing nine (9) months from the Launch Date and
ending twelve (12) months from the Launch Date

	 	XXXXX% of the Profit
	 
	 	 
	Commencing twelve (12) months from the Launch Date
and thereafter

	 	XXXXX% of the Profit

(b) for the Anchen Products XXXXX, XXXXX percent (XXXXX%) of
the Profit.”

(2) Teva hereby grants to Impax a non-exclusive sublicense
(XXXXX)
to all license rights granted from Biovail to Teva under the License Agreement by and between Teva
and Biovail dated the same date hereof (the “Biovail License Agreement”) to the extent necessary
for Impax to manufacture and supply to Teva the Impax Products to the extent such rights are
provided to Teva in the Biovail License Agreement.

(3) Teva shall have sole discretion to decide to Market at any time XXXXX. Further,
Teva shall have the discretion to decide to XXXXX. In the event that Teva XXXXX for purposes of Section 2.21
of the Agreement, and for purposes of determining the Impax Margin payable with respect thereto.
The term XXXXX.

(4) Teva warrants that in the event that it launches a XXXXX.

 

 

EXECUTION COPY

(5) Clause (2) of the proviso added by Section 1.1(e) of the Amendment, and revised by the letter
agreement between Teva and Impax dated September 13, 2006 with respect to the 150mg Bupropion
Products, shall be deleted in its entirety as it relates to the 150mg Bupropion Products and shall
read as follows: “all amounts paid by Teva and/or its Affiliates to Anchen and Biovail (or their
respective affiliates).”

(6) Impax agrees on behalf of itself and its Affiliates that none of them shall, directly or
indirectly, in any regulatory, judicial or other forum, challenge or contest the first to file
exclusivity for the 150mg Ancben,Product.

(7) Teva represents and warrants on behalf of itself and its Affiliates that it is unaware of any
fact that would form a basis to challenge the first to file exclusivity for the 150mg Anchen
Product.

The Agreement, as amended by the foregoing, shall remain in full force and effect. This letter
agreement shall be a legally binding agreement between Teva and Impax. This letter agreement may
be executed in two or more counterparts, each of which shall be deemed an original but all of
which, taken together, shall constitute one and the same instrument.

(Remainder of page intentionally left blank)

 

 

This letter agreement may be delivered by facsimile transmission and receipt of facsimile copy of any party’s signature shall be considered to be receipt of an original copy thereof.

Thank you.

Sincerely,

	 	 	 	 	 
	Teva Phartmaceuticals Curasco N.V.	 	 
	 
	 	 	 	 
	By:

	 	/s/ [Illegible]
	 	/s/ [Illegible]
	 

	 	 	 	 
	Name:
	 	 	 	 
	 

	 	 	 	 
	Title:

	 	Managing Director
	 	Managing Director
	 

	 	 	 	 

Read and Agreed to::

This 9th day of February, 2007

	 	 	 	 	 
	Impax Laboratories, Inc.	 	 
	 
	 	 	 	 
	By:

	 	/s/ Larry Hsu
 

	 	 
	Name:

	 	Larry Hsu
 

	 	 
	Title:

	 	CEO/President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]